Skip to main content

Table 4 Model results

From: Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran

Strategy

Cost ($)

Incr Cost ($)

Eff (QALYs)

Incr Eff (QALYs)

ICER ($/QALYs)

ADA

6,608

382

3.95

0.29

1,301

TCZ

6,990

4.24

  1. Abbreviations: ADA, Adalimumab; TCZ, Tocilizumab
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us